Background alzheimers Shape Background alzheimers Shape Background alzheimers Shape
Grants > Mechanisms of Inhibitory Neuron Vulnerability to Alzheimer’s Disease Updated On: Ene. 20, 2025
Alzheimer's Disease Research Grant

Mechanisms of Inhibitory Neuron Vulnerability to Alzheimer’s Disease

Cells & Circuits
a headshot of Dr. Zamponi

Principal Investigator

Emiliano Zamponi, PhD

Columbia University

New York City, NY, USA

About the Research Project

Program

Alzheimer's Disease Research

Award Type

Standard

Award Amount

$200,000

Active Dates

July 01, 2024 - June 30, 2026

Grant ID

A2024032F

Mentor(s)

Franck Polleux, PhD, Columbia University

Goals

To understand the mechanisms that control mitochondrial composition and function in fast-spiking parvalbumin-positive interneurons and how these are affected in Alzheimer’s disease.

Summary

Inhibitory interneurons, one of the key players in human cognitive processes, are among the first neuronal populations affected by AD onset. I propose their elevated energy consumption rates make these interneurons more vulnerable to AD. Using multiple innovative approaches, I will investigate three fundamental aspects underlying inhibitory interneuron vulnerability to AD. By completing the aims of my proposal, I expect to gain new insights into the pathological basis of this socially devastating neurological condition and contribute to develop novel therapeutic approaches.

Unique and Innovative

The most innovative aspects of my proposal are:

  1. The hypothesis: the role of mitochondrial metabolism in fast-spiking PN-INs remains largely unexplored despite extensive knowledge on the functional defects observed in this neuronal subtype at AD onset.
  2. The methodology: I will use cutting-edge microscopy and biochemical approaches to probe the functional properties of PV-INs during early stages of AD.
  3. The research approach: I will perform all my experiments in vivo using a validated AD mouse model which is significantly more relevant than non-mammalian models or in vitro approaches.

Foreseeable Benefits

A major challenge in AD research is to identify the initial pathological events that trigger neuronal dysfunction in this neurological disorder. Since PV-IN impairment is one of the earliest abnormalities detected in both patients and animal models of AD, I propose to test whether mitochondrial bioenergetics in PV-INs are affected across disease onset in a well-established AD mouse model. By pursuing these aims, I will provide new insights into the mechanisms underlying PV-IN dysfunction at early stages of AD and identify potential targets for the development of novel therapeutic approaches.